Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.
Something looks off?